This cohort quantifies how often stroke patients receive non-antiplatelet CYP2C19-metabolized drugs, arguing that genotype results obtained for clopidogrel selection carry broad, durable value across a patient's medication list.
CYP2C19 genotype testing extends beyond antiplatelet use in stroke patients.
CYP2C19 genotype testing can inform the prescribing of both antiplatelet and non-antiplatelet drugs after stroke, impacting patient care. 81% of stroke patients were co-prescribed a CYP2C19-metabolized drug at discharge, increasing to 83% in follow-up, highlighting the relevance of genotype-informed prescribing. CYP2C19 genotype testing at discharge may guide broader prescribing beyond antiplatelets, especially with increasing drug exposure over time. CYP2C19 genotype testing may guide more extensive prescribing decisions post-stroke.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Swire CC, Lambarth AT, Saleem A, Burrage DR
Citation:Swire CC, Lambarth AT, Saleem A, et al. Exposure to CYP2C19-metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing. British journal of clinical pharmacology. 2026. doi:10.1002/bcp.70722